🟢 Strong Evidence
Starting September 2026, the National Health Service (NHS) in England will extend respiratory syncytial virus (RSV) vaccination to thousands of additional vulnerable adults, broadening access beyond the initial rollout to older populations. The expansion targets adults aged 65–74 with chronic respiratory diseases and those with immunosuppression due to disease or treatment, substantially widening the eligible population for this preventive intervention.
Key takeaways
- RSV vaccine eligibility expands from September 2026 to include all adults aged 65–74 with chronic respiratory disease or immunosuppression
- RSV causes serious lower respiratory tract infections in elderly and immunocompromised populations, with increased hospitalization and mortality risk
- The vaccine programme follows successful use in immunocompetent adults aged 75 and older during the initial NHS rollout
- Chronic respiratory diseases and immunosuppressive conditions substantially increase RSV-related morbidity and mortality in older adults
RSV Vaccine Eligibility Expansion by Population Group
NHS England rollout phases: initial cohort vs. expanded eligibility, 2026
Source: NHS England, 2026 | Georgian Medical Journal News
RSV in older and immunocompromised populations: clinical burden
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract infection in older adults and immunocompromised individuals. According to WHO fact sheets on RSV, the virus causes acute bronchiolitis and pneumonia, with particular severity in adults aged 60 years and older, as well as those with underlying chronic conditions including chronic obstructive pulmonary disease (COPD) and asthma.
Immunosuppression—whether due to HIV/AIDS, chemotherapy, organ transplantation, or immunosuppressive medications—substantially elevates the risk of severe RSV disease and hospitalization. The pathophysiology involves both direct viral cytotoxicity and dysregulated immune response, making this population particularly vulnerable to complications.
Adults aged 65–74 with chronic respiratory disease or immunosuppression will now be eligible for NHS RSV vaccination from September 2026, reflecting mounting evidence of severe RSV-related morbidity and mortality in these high-risk groups.
— NHS England, Vaccination Programme Update, 2026
Clinical evidence supporting expanded vaccine rollout
The decision to expand RSV vaccination eligibility aligns with published evidence on vaccine efficacy and the burden of RSV-attributable disease in at-risk populations. The Clinical Updates section at GMJ News has previously documented RSV vaccine trials demonstrating substantial reductions in severe RSV lower respiratory tract disease in older adults.
Chronic respiratory diseases—including COPD, asthma, and interstitial lung disease—compromise respiratory reserve and increase both susceptibility to viral infection and risk of severe outcomes. Similarly, immunosuppression impairs the host response to respiratory pathogens, heightening vulnerability to prolonged viral replication and secondary bacterial superinfection. These populations therefore represent a logical target for RSV immunization alongside the baseline cohort of adults aged 75 and older.
Implementation and access considerations
The NHS expansion from September 2026 requires primary care identification and outreach to eligible individuals aged 65–74 with documented chronic respiratory disease or verified immunosuppression. This will likely involve systematic review of general practice disease registers and liaison with secondary care specialists managing immunocompromised patients. The Health Policy framework emphasizes ensuring equitable access to preventive interventions across all eligible populations.
Implementation challenges may include awareness among clinicians and patients, identification of all eligible individuals (particularly those with non-coded or undocumented chronic conditions), and adequate vaccine supply. Clear communication to primary care teams and use of invitation systems similar to those employed in seasonal influenza vaccination campaigns will be essential to maximizing uptake.
What this means
Frequently asked questions
Who is eligible for the RSV vaccine from September 2026?
All adults aged 65–74 living with a chronic respiratory disease (such as COPD or asthma) and those with immunosuppression due to disease or treatment are now eligible, according to NHS England. Adults aged 75 and older remain eligible as part of the baseline programme.
Why is RSV vaccination being expanded to younger age groups?
Chronic respiratory diseases and immunosuppressive conditions substantially elevate the risk of severe RSV-related pneumonia and hospitalization, even in younger older adults. The expansion reflects evidence that these high-risk groups derive substantial benefit from RSV vaccination.
How do I know if I am immunosuppressed and eligible?
Immunosuppression includes conditions such as HIV/AIDS, cancer requiring chemotherapy, solid organ or stem cell transplantation, and use of immunosuppressive medications (such as corticosteroids or biologics for rheumatoid arthritis). Your GP can confirm eligibility based on your medical history and current treatments.
The NHS expansion of RSV vaccination to vulnerable adults aged 65–74 represents a rational extension of the vaccine programme based on clinical evidence and disease burden. As implementation proceeds from September 2026, close monitoring of uptake rates, vaccine effectiveness in real-world conditions, and any adverse events will be important to assess the public health impact of this broader strategy in preventing winter respiratory disease in high-risk populations.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
